NEWS:MeRes100 findings to feed into a large randomized trial

Posted by:info on 2018-06-27 Wed
53
reads

Summary

First-generation scaffolds were large devices 150 µm thick and had several limitations as a result; apart from being difficult to use with poor deliverability, one of their biggest deficiencies was safety, with high scaffold thrombosis rates. At EuroPCR 2018, investigator Ashok Seth presented findings on the MeRes100, the first ever bioresorbable scaffold with a strut thickness of 100 µm. He describes the “fascinating characteristics” and “unique architecture” of the scaffold and outlines the advantages conferred by its PLLA backbone with a sirolimus-eluting coating and its availability in a variety of sizes. Discover his thoughts on the 2-year clinical optimized computed tomography (OCT) and intravascular ultrasound (IVUS) first-in-human data on MeRes100 in 108 patients with coronary artery disease. The “extremely favorable” and “encouraging” results will form the basis of a pivotal 2000-patient, randomized study comparing MeRes100 to a Xience everolimus-eluting stent that is due to commence later this year. Watch to learn more…



Click here for more information

MeRes100 findings to feed into a large randomized trial